Jaime Rosenberg

September 11, 2021

From the decision analysis came an agreement that reimbursement for an orphan drug should be based primarily on its effect on health-related quality of life, its effectiveness, and the availability of other treatment options.

September 11, 2021

According to researchers, new findings may have important implications for expanding the use of measurable residual disease (MRD) in multiple myeloma.

September 10, 2021

In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.

September 06, 2021

Unlike most other cancers, the progression of hairy cell leukemia is largely driven by extended cell survival rather than increased proliferative cell fractions.

September 06, 2021

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

September 04, 2021

The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

September 03, 2021

Most studies to date that show efficacy with ruxolitinib in this setting have been in adult patients.

September 02, 2021

The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.

September 01, 2021

The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.

August 31, 2021

This study protocol comes amid a paradigm shift in the treatment of advanced-stagen non–small cell lung cancer (NSCLC) following the emergence and uptake of immunotherapy.